CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT02071888
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:36:52.009125+00:00
- Published At
- 2018-07-18T00:00:00+00:00
- Record Updated At
- 2018-07-18
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Non-Hodgkin\u0027s Lymphoma (NHL)", "Multiple Myeloma", "Waldenstrom\u0027s Macroglobulinemia (WM)", "Other B-cell NHL Subtypes, Including WM", "T-cell NHL"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2018-07-18"- protocolSection.identificationModule.nctId
"NCT02071888"- protocolSection.identificationModule.officialTitle
"A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.